Summary & Overview
HCPCS Level II J7614: Levalbuterol Inhalation Solution, 0.5 mg Unit Dose
HCPCS Level II code J7614 denotes levalbuterol inhalation solution, an FDA-approved, non-compounded unit-dose (0.5 mg) respiratory bronchodilator formulated for administration through durable medical equipment. This code matters nationally because it standardizes billing for a commonly used inhaled bronchodilator delivered via nebulizer or other DME, affecting claims processing, coverage determinations, and procurement for outpatient and home-respiratory care.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise understanding of the clinical context for J7614, typical sites of service, and the payer landscape relevant to coverage and billing. The publication outlines benchmarks where available, summarizes applicable policy considerations, and explains how the code fits into respiratory DME delivery workflows.
The report provides actionable reference information for billing teams, revenue cycle leaders, and clinical managers responsible for respiratory therapy services. Data not available in the input is noted where appropriate; the focus remains on clarifying the code definition, service context, and the national payer set most often implicated in claims for unit-dose levalbuterol via DME.
Billing Code Overview
HCPCS Level II code J7614 represents levalbuterol inhalation solution, FDA-approved final product, non-compounded, administered through durable medical equipment (DME), unit dose, 0.5 mg. The service type is inhalation bronchodilator therapy provided as a prepared, unit-dose respiratory medication intended for administration via DME such as a nebulizer. The typical site of service is outpatient settings where DME is used, including clinics, outpatient infusion or respiratory therapy suites, and home health environments when respiratory DME is deployed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a pediatric or adult with acute bronchospasm due to asthma or chronic obstructive pulmonary disease (COPD) who requires an inhaled short-acting beta-2 agonist administered via durable medical equipment (nebulizer) in an outpatient infusion or DME-based setting. The patient presents to a respiratory clinic, emergency department observation unit, or home health visit where a clinician orders J7614 (levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 0.5 mg). The workflow includes verification of the order, medication selection from pharmacy stock in unit-dose vials, preparation by a licensed clinician or respiratory therapist, connection to the patient’s nebulizer (DME), administration while monitoring vital signs and respiratory status, and documentation of dose, lot number, route, and response. Billing uses J7614 per unit dose dispensed; appropriate medical necessity is supported by a primary respiratory diagnosis and contemporaneous documentation of bronchospasm or wheezing and clinician oversight. Common scenarios include acute asthma exacerbation managed in clinic or ED observation, scheduled nebulized bronchodilator therapy for COPD exacerbation, or home nebulizer treatments provided during a skilled home health visit where the medication is supplied through DME channels.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 |